IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application No. 10/565,331

Confirmation No. 2246

Applicant: DeFrees et al.

Filed: September 11, 2006

TC/AU: 1644

Examiner: Phuong N. Huynh

Docket No.: 705704 (Client Reference No. NEO00266.1)

Customer No.: 23460

Commissioner for Patents P.O. Box 1450 Alexandria. VA 22313-1450

REVOCATION OF FORMER POWERS OF ATTORNEY AND NEW POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST

Sir:

Novo Nordisk A/S (hereinafter the "assignee") is the assignee of record of the entire interest of the above-identified U.S. patent application, and has a place of business at Bagsvaerd, Denmark.

Pursuant to 37 CFR 3.73(b), the undersigned has reviewed evidentiary documents establishing a chain of title from the inventor(s) to the assignee and, to the best of the undersigned's knowledge and belief, certifies that title is in the assignee. The chain of title from the inventor(s) to the assignee was recorded in the U.S. Patent and Trademark Office on December 20, 2006, at Reel 018662, Frame No. 0276; on March 17, 2009, at Reel 022404, Frame No. 0634; on February 23, 2009, at Reel 022441, Frame No. 0937; and on April 9, 2009 at Reel 022527. Frame No. 0614.

The assignee hereby revokes all previously given powers of attorney and appoints the following as its attorneys to prosecute and transact all business in the U.S. Patent and Trademark Office connected with the application, including receiving all documents issued

by the U.S. Patent and Trademark Office based thereon; filing continuation, continuation-inpart and divisional applications based thereon; paying any and all fees, including maintenance fees for any resulting patent; and filing for reissues and extensions and requesting reexamination of any resulting patent, with all such powers to be exercised separately or collectively:

Customer Number

23460

The assignee requests that correspondence concerning this application be directed to the above-mentioned Customer Number.

The assignee also requests that all telephone calls be directed to John Kilyk, Jr., of Leydig, Voit & Mayer, Ltd. at (312) 616-5600.

Date: <u>23 12 /07 709</u>

Lars Kellberg

Corporate Vice President, Corporate Patents

Novo Nordisk A/S